{
  "id": 18479790,
  "title": "Genmab shares fall 3% after Q3 revenue slightly misses expectations",
  "url": "https://urgent.news/2026/11/06/genmab-shares-fall-3-after-q3-revenue-slightly-misses-expectations",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-06T09:53:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/genmab-ninemonth-revenue-rises-22-as-latestage-pipeline-delivers-5005279"
  },
  "original_language": "en",
  "account": "Shares of Danish biotech Genmab slipped by more than 3% after the company's third-quarter revenue fell slightly short of expectations. Operating expenses surged 35% to $2.02 billion, driven by investments in the company's drug pipeline and preparations for upcoming product launches, including a $87 million charge related to the Merus integration. Despite the revenue miss, Genmab's operating profit dipped to $986 million from $1.01 billion, while adjusted operating profit rose to $1.11 billion from $1.02 billion. For the first nine months of 2026, revenue grew 22% to $3.24 billion, propelled by higher royalties from Darzalex and Kesimpta, as well as strong sales of the cancer drug Epkinly. Royalty revenue climbed 22% to $2.70 billion, thanks to a 19% increase in Johnson & Johnson's net sales of Darzalex to $12.41 billion. Global net sales of Epkinly, also known as Tepkinly, jumped 47% to $491 million. Recently, epcoritamab received approval in Europe and Japan for use alongside another treatment in adults with relapsed or refractory follicular lymphoma. Genmab has also initiated two Phase 3 trials of petosemtamab for colorectal cancer. CEO Jan van de Winkel highlighted that the company is entering a data-rich fourth quarter following the delivery of pivotal trial results for three late-stage drugs - epcoritamab, Rina-S (rinatabart sesutecan), and petosemtamab - which support multiple regulatory submissions and potential launches in 2027.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}